Press Releases
-
Feb 02 ,2023
Gain to present new preclinical data on its lead programs in GBA1-related diseases BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present new preclinical data at the following upcoming scientific and...
Jan 12 ,2023BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the...
Nov 10 ,2022Presented New Preclinical Data at Recent Medical Meetings ShowingDisease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer andAppointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securitiesas of September 30, 2022 Provides Strong Financial Foundation andExtends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain...
Presentation
January, 2023
Jan 01, 2021
November 11, 2021